(Q38045652)

27 August 2017

Uterine papillary serous cancer: a review of the literature (English)

1 reference

27 August 2017

Marcela G del Carmen

1

1 reference

27 August 2017

Michael Birrer

series ordinal

2

1 reference

27 August 2017

John O Schorge

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

20 September 2012

1 reference

27 August 2017

1 reference

27 August 2017

127

1 reference

27 August 2017

3

1 reference

27 August 2017

651-661

1 reference

27 August 2017

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Endometrial papillary serous carcinoma: patterns of spread and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Clear-cell and papillary serous cancer: treatment options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Uterine papillary serous carcinoma: state of the state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Two pathogenetic types of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Body Mass and Endometrial Cancer Risk by Hormone Replacement Therapy and Cancer Subtype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Body size in relation to cancer of the uterine corpus in 1 million Norwegian women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Racial disparities in blacks with gynecologic cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Prognostic determinants in patients with stage I uterine papillary serous carcinoma: a 15-year multi-institutional review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Association between uterine serous carcinoma and breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Is Uterine Papillary Serous Adenocarcinoma a Manifestation of the Hereditary Breast–Ovarian Cancer Syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

BRCA1 germline mutations in women with uterine serous papillary carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Risk of Endometrial Carcinoma Associated with BRCA Mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Patients having prophylactic surgery for family history or known genetic mutations: why save the uterus?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Molecular and pathologic aspects of endometrial carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Stage IA uterine serous carcinoma: a study of 13 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Noninvasive papillary serous carcinoma of the endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Uterine papillary serous carcinoma: patterns of metastatic spread

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Endometrial glandular dysplasia and endometrial intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Transvaginal sonography of the endometrium in women with postmenopausal bleeding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: detection of pelvic nodal metastases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

18F-FDG PET in the management of endometrial cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

CA 125: a useful marker in endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

The role of optimal debulking in advanced stage serous carcinoma of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Complete clinical responses to neoadjuvant chemotherapy for uterine serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Neoadjuvant chemotherapy in uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

What staging surgery should be performed on patients with uterine papillary serous carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

The role of omentectomy during the surgical staging of uterine serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Minimal uterine serous carcinoma: a clinicopathological study of 40 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

The role of surgical cytoreduction in Stage IV endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Role of cytoreduction in stage III and IV uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Outcomes in surgical stage I uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Optimal management for surgically Stage 1 serous cancer of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Carboplatin and paclitaxel in advanced or metastatic endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Treatment of uterine papillary serous carcinoma with paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

The role of abdominal-pelvic radiotherapy in the management of uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Outcome and pattern of failure in pathologic stage I–II papillary serous carcinoma of the endometrium: Implications for adjuvant radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Uterine serous carcinoma: a comparison of therapy for advanced-stage disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Uterine papillary serous carcinoma. A clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Letter to the Editor referring to the manuscript entitled: "Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study" recently reported by Fleming et al., (Gynecol Oncol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

Uterine papillary serous carcinoma: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

inferred from DOI database lookup

7 January 2021

based on heuristic

Recurrence in noninvasive endometrial carcinoma. Relationship to uterine papillary serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.09.012

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2012.09.012

1 reference

27 August 2017

1 reference